Core Insights - Avoro Capital Advisors LLC acquired a new stake in Oruka Therapeutics, purchasing 1,333,340 shares valued at approximately $25.64 million, making it the 24th largest position in their portfolio [2] - Institutional investors and hedge funds currently own 56.44% of Oruka Therapeutics, with significant recent activity from firms like Goldman Sachs, Geode Capital Management, and JPMorgan Chase [3] - Insider Joana Goncalves sold 7,000 shares at an average price of $32.37, representing a 17.07% decrease in her position, while insiders have sold a total of 21,000 shares valued at $663,530 in the last ninety days [4] Analyst Ratings and Price Targets - Analysts have shown positive sentiment towards Oruka Therapeutics, with Wedbush reaffirming an "outperform" rating and a target price of $45, while BTIG Research set a higher target of $73 [5][6] - Barclays raised its price target from $48 to $50, and UBS Group initiated coverage with a "buy" rating and a $50 target, indicating strong buy-side conviction [6] - The consensus rating for Oruka Therapeutics is "Moderate Buy" with an average price target of $56.67 [7] Financial Performance - Oruka Therapeutics reported earnings per share of ($0.45), exceeding the consensus estimate of ($0.61) by $0.16, which may reduce short-term execution risk [9] - The company has a market capitalization of $1.94 billion, with a P/E ratio of -21.51, indicating it is currently operating at a loss [8] Company Overview - Oruka Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel peptide-based therapies for oncology, utilizing a proprietary stapled peptide platform [10] - The lead candidate, ONCT-01, is in Phase 1 clinical trials for advanced solid tumors, assessing safety, tolerability, and preliminary efficacy [10]
Avoro Capital Advisors LLC Makes New Investment in Oruka Therapeutics, Inc. $ORKA